Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SGEN Seagen Inc. daily Stock Chart
SGEN [NASD]
Seagen Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.50 Insider Own0.90% Shs Outstand173.41M Perf Week-2.00%
Market Cap34.91B Forward P/E994.55 EPS next Y0.20 Insider Trans-67.18% Shs Float172.78M Perf Month9.75%
Income-255.70M PEG- EPS next Q0.50 Inst Own- Short Float2.52% Perf Quarter14.92%
Sales1.02B P/S34.38 EPS this Y32.10% Inst Trans- Short Ratio4.57 Perf Half Y33.52%
Book/sh10.46 P/B18.83 EPS next Y115.00% ROA-11.90% Target Price193.44 Perf Year96.39%
Cash/sh5.05 P/C38.98 EPS next 5Y- ROE-14.10% 52W Range90.57 - 213.94 Perf YTD72.34%
Dividend- P/FCF- EPS past 5Y-9.20% ROI-11.80% 52W High-7.96% Beta1.15
Dividend %- Quick Ratio4.40 Sales past 5Y26.20% Gross Margin90.10% 52W Low117.42% ATR5.73
Employees1605 Current Ratio4.70 Sales Q/Q27.30% Oper. Margin-32.90% RSI (14)55.23 Volatility2.76% 2.91%
OptionableYes Debt/Eq0.00 EPS Q/Q75.10% Profit Margin-25.20% Rel Volume0.50 Prev Close200.66
ShortableYes LT Debt/Eq0.00 EarningsOct 29 AMC Payout- Avg Volume954.23K Price196.92
Recom2.20 SMA20-1.11% SMA5011.60% SMA20032.88% Volume479,603 Change-1.86%
Sep-22-20Reiterated Stifel Hold $145 → $165
Aug-24-20Resumed Berenberg Buy $187
Jul-31-20Reiterated H.C. Wainwright Buy $175 → $200
Jul-24-20Downgrade Piper Sandler Overweight → Neutral
May-26-20Initiated JMP Securities Mkt Outperform $185
May-01-20Upgrade Guggenheim Neutral → Buy
May-01-20Reiterated Needham Buy $157 → $163
Feb-18-20Downgrade Barclays Overweight → Equal Weight $124
Feb-12-20Reiterated H.C. Wainwright Buy $140 → $150
Feb-11-20Reiterated Goldman Buy $126 → $165
Jan-28-20Initiated BMO Capital Markets Outperform
Jan-27-20Initiated BMO Capital Markets Outperform
Jan-02-20Downgrade Guggenheim Buy → Neutral
Dec-10-19Initiated Morgan Stanley Equal-Weight
Dec-03-19Resumed BofA/Merrill Neutral
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Aug-26-19Initiated BTIG Research Neutral
Jul-18-19Initiated Deutsche Bank Hold $79
Oct-22-20 12:33PM  
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks
12:27PM  
Are Investors Undervaluing Seagen Inc. (NASDAQ:SGEN) By 21%?
Simply Wall St.
Oct-13-20 01:33PM  
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
Zacks
08:00AM  
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020
Business Wire
Oct-12-20 06:45AM  
Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
Business Wire
06:45AM  
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
PR Newswire
Oct-08-20 08:00AM  
Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.
Business Wire
Oct-07-20 09:44AM  
Why Seattle Genetics Stock Jumped 24% in September
Motley Fool
Oct-05-20 11:13AM  
Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?
TheStreet.com
Oct-03-20 06:55AM  
Next Coronavirus Market Crash: Where to Invest $10,000
Motley Fool
Oct-01-20 12:42PM  
Seattle Genetics Hits New Highs and a Strategy Adjustment Is Needed
TheStreet.com
Sep-28-20 05:33PM  
Dow Jones Futures: Stock Market Rally Needs To Turn Up The Volume; Target, Adobe, Nvidia Lead Top Stocks In Buy Zones
Investor's Business Daily
Sep-24-20 07:33AM  
Seattle Genetics' Shares March Higher, Can It Continue?
Zacks
Sep-21-20 10:20AM  
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Business Wire
Sep-18-20 01:17PM  
Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival
Zacks
12:38PM  
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
Zacks
06:45AM  
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Business Wire
06:45AM  
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
PR Newswire
Sep-16-20 10:09AM  
Analysts Just Published A Bright New Outlook For Seattle Genetics, Inc.'s (NASDAQ:SGEN)
Simply Wall St.
09:47AM  
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
Zacks
Sep-15-20 12:53PM  
Seattle Genetics Up on Two New Oncology Deals With Merck
Zacks
09:51AM  
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
Zacks
Sep-14-20 07:01PM  
Jim Cramer: Is This Market Undervalued?
TheStreet.com +14.55%
05:40PM  
Merck Inks Multibillion-Dollar Deal With Seattle Genetics, Including Equity
Motley Fool
04:39PM  
Seattle Genetics Pact With Drug Giant Merck Sends SGEN Stock Soaring
Investor's Business Daily
04:34PM  
US STOCKS-Wall Street closes broadly higher on deal news, vaccine hopes
Reuters
04:00PM  
US STOCKS-Wall Street closes broadly higher on deal news, vaccine hopes
Reuters
03:55PM  
Analyst Report: Seattle Genetics, Inc.
Morningstar Research
01:41PM  
Merck To Buy $1B Seattle Genetics Stake For Oncology Collab
SmarterAnalyst
12:48PM  
US STOCKS-Wall Street climbs on mega mergers, vaccine hopes
Reuters
11:15AM  
Mercks Partnership With Seattle Genetics Is a Bet on a New Anticancer Strategy
Barrons.com
10:30AM  
How About That Merck and Seattle Genetics Deal?
TheStreet.com
09:55AM  
Merck Inks Up to $4.5 Billion Seattle Genetics Cancer Deal
Bloomberg
09:51AM  
Looking Into Seattle Genetics's Return On Capital Employed
Benzinga
09:45AM  
Dow Jones Today, Stocks Open Higher On Nvidia, Gilead, Oracle Merger News; Micron Pops On Upgrade
Investor's Business Daily
09:38AM  
Merck Takes Seattle Genetics Stake, Plans Cancer-Drug Venture
TheStreet.com
08:01AM  
Shares of Seattle Genetics jump as Merck makes up to $4.2 billion investment
MarketWatch
06:45AM  
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Business Wire
Sep-09-20 08:41PM  
Hedge Funds Never Been This Bullish On Seattle Genetics, Inc. (SGEN)
Insider Monkey
Sep-03-20 08:00AM  
Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Business Wire
Sep-02-20 02:12PM  
Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years
Simply Wall St.
Aug-29-20 11:32AM  
Seattle Genetics (SGEN) Down 10.2% Since Last Earnings Report: Can It Rebound?
Zacks
Aug-28-20 11:52AM  
Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo
Zacks
Aug-27-20 08:10AM  
Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)
Business Wire
08:00AM  
Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020
Business Wire
Aug-18-20 08:00AM  
Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors
Business Wire
Aug-12-20 08:00AM  
Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDAs Project Orbis Initiative
Business Wire
Aug-06-20 08:00AM  
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval
Business Wire
Jul-31-20 08:32PM  
Seattle Genetics (SGEN) Q2 2020 Earnings Call Transcript
Motley Fool
11:16AM  
Seattle Genetics (SGEN) Q2 Earnings Beat, Adcetris Aids Sales
Zacks
Jul-30-20 05:15PM  
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
Zacks
04:02PM  
Seattle Genetics Reports Second Quarter 2020 Financial Results
Business Wire
Jul-28-20 06:23AM  
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
Motley Fool
Jul-24-20 12:10PM  
Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation
Benzinga
Jul-23-20 12:33PM  
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks
Jul-19-20 08:58AM  
What Can We Learn About Seattle Genetics' (NASDAQ:SGEN) CEO Compensation?
Simply Wall St.
Jul-12-20 01:20PM  
Did Hedge Funds Make The Right Call On Seattle Genetics, Inc. (SGEN) ?
Insider Monkey
Jul-09-20 08:00AM  
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020
Business Wire
Jul-06-20 10:28AM  
Seattle Genetics' Adcetris Progresses Well Amid Competition
Zacks
Jul-03-20 10:03AM  
Why Seattle Genetics Shares Climbed 48.7% in the First Half
Motley Fool
Jun-30-20 07:41AM  
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
Benzinga
Jun-29-20 04:30PM  
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Business Wire
Jun-23-20 09:00PM  
Edited Transcript of SGEN.OQ earnings conference call or presentation 30-Apr-20 8:30pm GMT
Thomson Reuters StreetEvents
Jun-22-20 11:00AM  
Here's My Take on Seattle Genetics
TheStreet.com
08:12AM  
Dow Jones Futures Slash Losses: Stock Market Rally Faces Coronavirus Wave; Apple WWDC, Tesla News In Focus
Investor's Business Daily
Jun-18-20 08:00AM  
Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates
Business Wire
Jun-09-20 06:11PM  
Do Hedge Funds Love Seattle Genetics, Inc. (SGEN)?
Insider Monkey
Jun-03-20 08:00AM  
Seattle Genetics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
Business Wire
May-30-20 11:31AM  
Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report?
Zacks
May-29-20 08:00AM  
Seattle Genetics Announces Positive Results from Exploratory Analyses of HER2CLIMB for TUKYSA (tucatinib) in Brain Metastases Patients With HER2-Positive Breast Cancer
Business Wire
May-22-20 07:00PM  
Anterix and Bausch Holding See Activist Action
Barrons.com
May-19-20 01:02PM  
Charting a headline breakout attempt, S&P 500 nails major resistance (2,954)
MarketWatch
May-15-20 01:20PM  
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma
Zacks
11:20AM  
Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners
Zacks
May-14-20 08:00AM  
Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma
Business Wire
May-13-20 05:12PM  
Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting
Business Wire
May-12-20 08:00AM  
Seattle Genetics Announces the Approval of TUKYSA (tucatinib) in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer
Business Wire
May-09-20 02:19PM  
The Nasdaq is now up for the year here are the indexs best-performing stocks
MarketWatch
May-08-20 10:39AM  
Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected
Zacks
May-07-20 05:42PM  
Analysts See Seattle Genetics Profitable in 2022
GuruFocus.com
May-06-20 11:34AM  
Industry Analysts Just Upgraded Their Seattle Genetics, Inc. (NASDAQ:SGEN) Revenue Forecasts By 10%
Simply Wall St.
May-05-20 08:00AM  
Seattle Genetics to Present at the BofA Securities Virtual Health Care Conference 2020
Business Wire +6.21%
May-04-20 01:25PM  
Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales
Zacks +6.95%
11:45AM  
Seattle Genetics Soars on Cancer Drugs: Here's How to Play the Stock
TheStreet.com
May-01-20 02:30PM  
Seattle Genetics Inc (SGEN) Q1 2020 Earnings Call Transcript
Motley Fool +6.13%
Apr-30-20 05:15PM  
Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates
Zacks
04:02PM  
Seattle Genetics Reports First Quarter 2020 Financial Results
Business Wire
11:12AM  
Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat
Zacks
Apr-29-20 12:00PM  
Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy
Zacks
10:05AM  
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
Zacks
Apr-28-20 12:11PM  
Will Seattle Genetics Continue to Surge Higher?
Zacks
Apr-24-20 08:00AM  
Seattle Genetics Announces Change to Virtual Format for 2020 Annual Meeting
Business Wire
Apr-23-20 12:32PM  
Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for
Zacks
Apr-22-20 02:20PM  
Shares of Immunomedics rise 1% on FDA approval of breast-cancer drug
MarketWatch
10:00AM  
Seattle Genetics (NASDAQ:SGEN) Is In A Strong Position To Grow Its Business
Simply Wall St.
Apr-21-20 12:34PM  
With FDA Approvals in Hand, These 2 Biotech Stocks Are on Wall Streets Radar
TipRanks
Apr-20-20 11:42AM  
Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug
Zacks
07:21AM  
Seattle Genetics Breast Cancer Drug Approved Months Ahead of Schedule
SmarterAnalyst
Apr-17-20 02:46PM  
Seattle Genetics' stock rises on early FDA nod for breast-cancer drug
MarketWatch
02:27PM  
Seattle Genetics Announces U.S. FDA Approval of TUKYSA (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
Business Wire
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIU JEAN IGC/EVP, Leg AffairsSep 21Option Exercise36.779,954366,01958,642Sep 23 07:28 PM
LIU JEAN IGC/EVP, Leg AffairsSep 14Sale170.0011,6101,973,70048,688Sep 16 06:53 PM
HIMES VAUGHN BChief Technical OfficerSep 09Option Exercise15.468,000123,680194,829Sep 11 06:25 PM
HIMES VAUGHN BChief Technical OfficerSep 09Sale147.558,0001,180,385186,829Sep 11 06:25 PM
SIMPSON TODD EChief Financial OfficerSep 01Sale155.8612,0911,884,512126,276Sep 02 07:24 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale155.693,585558,164186,829Sep 02 07:25 PM
DANSEY ROGER DChief Medical OfficerAug 31Sale155.694,611717,906117,882Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 31Sale155.6914,3512,234,367715,209Sep 02 07:24 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale155.694,187651,892138,367Sep 02 07:24 PM
ROMP CHARLES REVP, CommercialAug 31Sale155.691,133176,40257,942Sep 02 07:25 PM
LIU JEAN IGC/EVP, Leg AffairsAug 31Sale155.693,648567,97260,298Sep 02 07:25 PM
SIEGALL CLAY BPresident and CEOAug 21Option Exercise19.4210,299199,984729,560Aug 25 06:35 PM
ROMP CHARLES REVP, CommercialAug 18Sale158.174,027636,94159,075Aug 20 06:26 PM
SIEGALL CLAY BPresident and CEOAug 18Sale158.1727,0604,280,053719,261Aug 20 06:26 PM
SIMPSON TODD EChief Financial OfficerAug 18Sale158.179,2621,464,959142,554Aug 20 06:27 PM
HIMES VAUGHN BChief Technical OfficerAug 18Sale158.178,0541,273,892190,414Aug 20 06:23 PM
LIU JEAN IGC/EVP, Leg AffairsAug 18Sale158.176,8461,082,82363,946Aug 20 06:58 PM
DANSEY ROGER DChief Medical OfficerAug 17Sale157.7945071,006122,493Aug 17 09:40 PM
SIEGALL CLAY BPresident and CEOAug 10Option Exercise12.0028,475341,700729,955Aug 13 06:04 AM
SIEGALL CLAY BPresident and CEOAug 10Sale156.7428,4754,463,263718,339Aug 13 06:04 AM
SIMPSON TODD EChief Financial OfficerAug 03Sale165.7220,0003,314,418143,181Aug 05 07:14 PM
HIMES VAUGHN BChief Technical OfficerJul 17Option Exercise15.468,000123,680199,840Jul 21 07:48 PM
HIMES VAUGHN BChief Technical OfficerJul 17Sale179.428,0001,435,363191,840Jul 21 07:48 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.0028,472341,664734,660Jul 10 06:07 PM
SIEGALL CLAY BPresident and CEOJul 08Sale175.0828,4724,984,808718,339Jul 10 06:07 PM
ROMP CHARLES REVP, CommercialJul 02Sale167.49712119,25355,307Jul 07 06:34 PM
SIMPSON TODD EChief Financial OfficerJul 01Sale167.5811,5731,939,352163,181Jul 02 07:19 PM
LIU JEAN IGC/EVP, Leg AffairsJun 19Sale165.009,8771,629,70563,597Jun 22 07:46 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale158.892,162343,523109,608Jun 19 05:54 PM
DANSEY ROGER DChief Medical OfficerJun 16Sale157.15838131,692111,770Jun 17 07:24 PM
DANSEY ROGER DChief Medical OfficerJun 15Sale157.154,984783,236112,608Jun 17 07:24 PM
SIEGALL CLAY BPresident and CEOJun 08Option Exercise12.0028,472341,664724,939Jun 10 06:57 PM
SIEGALL CLAY BPresident and CEOJun 08Sale148.7728,4724,235,807718,339Jun 10 06:57 PM
BAKER BROS. ADVISORS LPDirectorMay 15Sale160.001,750,000280,000,0004,082,851May 19 06:03 PM
ROMP CHARLES REVP, CommercialMay 12Option Exercise15.466,942107,32359,517May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 12Sale166.006,9421,152,37252,575May 14 06:54 PM
ROMP CHARLES REVP, CommercialMay 08Option Exercise15.466,942107,32359,517May 08 07:54 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.0028,472341,664728,603May 12 07:51 PM
SIEGALL CLAY BPresident and CEOMay 08Sale161.0128,4724,584,311718,339May 12 07:51 PM
BAKER BROS. ADVISORS LPDirectorMay 08Sale158.50500,00079,250,0004,230,539May 08 05:47 PM
ROMP CHARLES REVP, CommercialMay 08Sale163.026,9421,131,66752,575May 08 07:54 PM
DANSEY ROGER DChief Medical OfficerMay 07Option Exercise65.1111,912775,590129,145May 08 07:42 PM
DANSEY ROGER DChief Medical OfficerMay 07Sale164.5011,9121,959,526117,233May 08 07:42 PM
BAKER BROS. ADVISORS LPDirectorMay 07Sale164.41168,24427,660,9474,272,736May 08 05:47 PM
BAKER BROS. ADVISORS LPDirectorMay 06Sale165.05390,07264,379,4734,286,935May 08 05:47 PM
SIEGALL CLAY BPresident and CEOMay 06Sale165.2325,4024,197,062718,339May 07 07:59 PM
WELCH DANIEL GDirectorMay 06Sale164.7915,0002,471,91955,263May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Option Exercise22.1539,059865,277188,563May 06 06:32 PM
AKKARAJU SRINIVASDirectorMay 05Option Exercise20.068,500170,51048,668May 07 07:58 PM
SIEGALL CLAY BPresident and CEOMay 05Sale166.0824,5984,085,341743,741May 07 07:59 PM
WELCH DANIEL GDirectorMay 05Sale166.7320,0003,334,64170,263May 07 07:59 PM
AKKARAJU SRINIVASDirectorMay 05Sale167.268,5001,421,71040,168May 07 07:58 PM
ROMP CHARLES REVP, CommercialMay 05Sale166.185,056840,22652,575May 07 07:59 PM
SIMPSON TODD EChief Financial OfficerMay 05Sale162.9426,8674,377,596161,696May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Option Exercise12.0014,167170,004175,863May 06 06:32 PM
SIMPSON TODD EChief Financial OfficerMay 04Sale147.0014,1672,082,556161,696May 06 06:32 PM
LIPPMAN MARC EDirectorMay 04Sale152.031,000152,030130,313May 06 06:19 PM
BAKER BROS. ADVISORS LPDirectorApr 23Option Exercise12.7635,000446,60045,860,149Apr 24 04:25 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.0028,472341,664779,866Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOApr 08Sale120.0128,4723,416,814758,784Apr 10 07:31 PM
SIEGALL CLAY BPresident and CEOMar 09Option Exercise12.0028,472341,664768,581Mar 11 06:51 PM
SIEGALL CLAY BPresident and CEOMar 09Sale110.0928,4723,134,578758,784Mar 11 06:51 PM
HIMES VAUGHN BChief Technical OfficerMar 06Option Exercise13.518,000108,117193,172Mar 10 08:12 PM
HIMES VAUGHN BChief Technical OfficerMar 06Sale114.918,000919,292188,674Mar 10 08:12 PM
DANSEY ROGER DChief Medical OfficerFeb 18Sale116.3335040,716107,659Feb 20 05:33 PM
SIEGALL CLAY BPresident and CEOFeb 10Option Exercise12.0028,472341,664768,723Feb 12 05:38 PM
SIEGALL CLAY BPresident and CEOFeb 10Sale114.6128,4723,263,110758,784Feb 12 05:38 PM
DANSEY ROGER DChief Medical OfficerFeb 03Sale108.5172778,887108,009Feb 05 06:08 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.0028,472341,664785,937Jan 10 07:08 PM
SIEGALL CLAY BPresident and CEOJan 08Sale111.3228,4723,169,433758,784Jan 10 07:08 PM
WELCH DANIEL GDirectorJan 07Option Exercise12.7617,500223,30090,263Jan 09 08:32 PM
DANSEY ROGER DChief Medical OfficerDec 16Sale114.072,000228,140101,146Dec 17 06:48 PM
SIEGALL CLAY BPresident and CEODec 09Option Exercise12.0028,472341,664773,011Dec 10 07:15 PM
SIEGALL CLAY BPresident and CEODec 09Sale114.5628,4723,261,641755,684Dec 10 07:15 PM
HIMES VAUGHN BChief Technical OfficerDec 06Option Exercise12.008,00096,000195,518Dec 10 07:14 PM
HIMES VAUGHN BChief Technical OfficerDec 06Sale117.168,000937,265187,518Dec 10 07:14 PM
DANSEY ROGER DChief Medical OfficerNov 25Option Exercise65.115,000325,550108,146Nov 27 05:32 PM
DANSEY ROGER DChief Medical OfficerNov 25Sale121.485,000607,388103,146Nov 27 05:32 PM
AKKARAJU SRINIVASDirectorNov 21Option Exercise19.0217,500332,85052,726Nov 22 06:35 PM
AKKARAJU SRINIVASDirectorNov 21Sale119.7817,5002,096,12040,168Nov 22 06:35 PM
LIPPMAN MARC EDirectorNov 18Option Exercise15.8935,000556,150148,813Nov 20 06:41 PM
DANSEY ROGER DChief Medical OfficerNov 18Option Exercise65.115,000325,550108,146Nov 20 06:45 PM
DANSEY ROGER DChief Medical OfficerNov 18Sale116.005,000580,000103,146Nov 20 06:45 PM
LIPPMAN MARC EDirectorNov 18Sale115.8035,0004,053,000131,313Nov 20 06:41 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.0028,472341,664776,483Nov 12 06:24 PM
SIEGALL CLAY BPresident and CEONov 08Sale107.6128,4723,063,816755,684Nov 12 06:24 PM
open in yahoo | open in reuters | open in google
affiliate | advertise | contact | privacy | help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.